Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience
M. Madsen, Dea Siggaard Stenbæk, Albin Arvidsson, et al.
European Neuropsychopharmacology (2021) Vol. 50, pp. 121-132
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

The neural basis of psychedelic action
Alex C. Kwan, David E. Olson, Katrin H. Preller, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 11, pp. 1407-1419
Closed Access | Times Cited: 166
Human brain effects of DMT assessed via EEG-fMRI
Christopher Timmermann, Leor Roseman, Sharad Haridas, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 13
Open Access | Times Cited: 129
Default Mode Network Modulation by Psychedelics: A Systematic Review
James J Gattuso, Daniel Perkins, Simon Ruffell, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 26, Iss. 3, pp. 155-188
Open Access | Times Cited: 101
Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses
Drummond E-Wen McCulloch, Gitte M. Knudsen, Frederick S. Barrett, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 138, pp. 104689-104689
Open Access | Times Cited: 76
A complex systems perspective on psychedelic brain action
Manesh Girn, Fernando E. Rosas, Richard E. Daws, et al.
Trends in Cognitive Sciences (2023) Vol. 27, Iss. 5, pp. 433-445
Closed Access | Times Cited: 42
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 28
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity
M. Madsen, Anja Sofie Petersen, Dea Siggaard Stenbæk, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 1, pp. 55-67
Closed Access | Times Cited: 16
Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development
R. C. Van Court, Matthew S. Wiseman, Kuno Meyer, et al.
Fungal Biology (2022) Vol. 126, Iss. 4, pp. 308-319
Open Access | Times Cited: 57
Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report
Drummond E-Wen McCulloch, Maria Zofia Grzywacz, Martin Bruun Madsen, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 54
Psychedelics and Neural Plasticity: Therapeutic Implications
Steven F. Grieco, Eero Ċastrén, Gitte M. Knudsen, et al.
Journal of Neuroscience (2022) Vol. 42, Iss. 45, pp. 8439-8449
Open Access | Times Cited: 44
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
M. Ishrat Husain, Nicole Ledwos, Elise Fellows, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 28
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Josh Allen, Shannon Dames, Claire J. Foldi, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 3, pp. 671-685
Closed Access | Times Cited: 13
Exploring mechanisms of psychedelic action using neuroimaging
David Erritzøe, Christopher Timmermann, Kate Godfrey, et al.
Nature Mental Health (2024) Vol. 2, Iss. 2, pp. 141-153
Closed Access | Times Cited: 11
Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones, et al.
Clinical Pharmacokinetics (2025)
Open Access | Times Cited: 1
Psychedelics, Sociality, and Human Evolution
José Manuel Rodríguez Arce, Michael Winkelman
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 49
Sustained effects of single doses of classical psychedelics in humans
Gitte M. Knudsen
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 145-150
Open Access | Times Cited: 37
Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects
Anders S. Olsen, Anders Lykkebo-Valløe, Brice Ozenne, et al.
NeuroImage (2022) Vol. 264, pp. 119716-119716
Open Access | Times Cited: 30
With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis
Daniel Villiger, Manuel Trachsel
Journal of Medical Ethics (2023) Vol. 49, Iss. 12, pp. 826-832
Open Access | Times Cited: 16
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
Anna Søndergaard, M. Madsen, Brice Ozenne, et al.
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 23
A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression
Meghan Hibicke, Hannah M. Kramer, Charles D. Nichols
Psychedelic Medicine (2023) Vol. 1, Iss. 1, pp. 54-67
Closed Access | Times Cited: 15
Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders
Andreas B. Wulff, Charles D. Nichols, Scott M. Thompson
Neuropharmacology (2023) Vol. 231, pp. 109504-109504
Open Access | Times Cited: 14
A computational account of the development and evolution of psychotic symptoms
Albert R. Powers, Peter Angelos, Alexandria Bond, et al.
Biological Psychiatry (2024)
Open Access | Times Cited: 5
Synthetic surprise as the foundation of the psychedelic experience
Roberto De Filippo, Dietmar Schmitz
Neuroscience & Biobehavioral Reviews (2024) Vol. 157, pp. 105538-105538
Open Access | Times Cited: 4
Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention
Oliver Rumle Hovmand, Mathias Ebbesen Jensen, Tobias Søgaard Juul, et al.
Journal of Psychoactive Drugs (2024), pp. 1-10
Closed Access | Times Cited: 4
Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
Petros Petridis, Jack Grinband, Gabrielle Agin-Liebes, et al.
Nature Mental Health (2024) Vol. 2, Iss. 11, pp. 1408-1414
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top